NCT02893761 Bergonie Institute Breast Cancer Database
| NCT ID | NCT02893761 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Bergonié |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 30,000 participants |
| Start Date | 1990-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30,000 participants in total. It began in 1990-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A database of breast cancer patients was established at Institute Bergonié since the 90s , to assess patients' survival, assess practice, search for prognostic factors.
Eligibility Criteria
Inclusion Criteria: * Breast cancer * Aged 18 years and over * First treatment at Bergonie Institute Exclusion Criteria: \-
Contact & Investigator
Gaetan Mac Grogan, MD
PRINCIPAL INVESTIGATOR
Institut Bergonié
Frequently Asked Questions
Who can join the NCT02893761 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02893761 currently recruiting?
Yes, NCT02893761 is actively recruiting participants. Contact the research team at g.macgrogan@bordeaux.unicancer.fr for enrollment information.
Where is the NCT02893761 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT02893761 clinical trial?
NCT02893761 is sponsored by Institut Bergonié. The principal investigator is Gaetan Mac Grogan, MD at Institut Bergonié. The trial plans to enroll 30,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.